Nanobiotix S.A. (NASDAQ:NBTX – Free Report) – Leerink Partnrs raised their FY2025 earnings per share (EPS) estimates for Nanobiotix in a research note issued on Thursday, April 25th. Leerink Partnrs analyst J. Chang now expects that the company will earn $1.07 per share for the year, up from their previous estimate of $1.06. The consensus estimate for Nanobiotix’s current full-year earnings is ($0.86) per share.
Nanobiotix Stock Down 2.9 %
Shares of NBTX stock opened at $5.74 on Monday. The stock has a 50-day simple moving average of $6.29 and a 200 day simple moving average of $6.55. Nanobiotix has a fifty-two week low of $1.75 and a fifty-two week high of $11.00.
Institutional Inflows and Outflows
Nanobiotix Company Profile
Nanobiotix SA, a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer.
Read More
- Five stocks we like better than Nanobiotix
- Investing In Automotive Stocks
- Snap Crackles and Pops on Surprise Profit and Raised Guidance
- The Significance of Brokerage Rankings in Stock Selection
- MarketBeat Week in Review – 4/22 – 4/26
- What Are Dividend Challengers?
- 3 Stocks Leading the U.S. Agriculture Comeback
Receive News & Ratings for Nanobiotix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nanobiotix and related companies with MarketBeat.com's FREE daily email newsletter.